+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Dementia Drugs Market by Indications, Drug Class - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5674964
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Dementia Drugs Market grew from USD 9.80 billion in 2023 to USD 10.78 billion in 2024. It is expected to continue growing at a CAGR of 10.39%, reaching USD 19.58 billion by 2030.

The dementia drugs market revolves around treatments aimed at improving cognitive function and managing symptoms for patients suffering from dementia-related disorders, including Alzheimer's disease. The necessity of dementia drugs arises from the growing prevalence of neurodegenerative conditions, driven by an ageing population and increasing life expectancy. The primary application of these drugs is to slow disease progression, manage behavioral symptoms, and enhance patient quality of life, with usage spanning healthcare settings such as hospitals, clinics, and home care environments. Key growth factors influencing this market include advancements in biomedical research, heightened awareness and diagnosis rates, and increased healthcare spending. However, challenges such as high research and development costs, stringent regulatory requirements, and limited efficacy of currently available drugs pose significant obstacles to market growth. Potential opportunities lie in the development of novel therapeutics, such as disease-modifying treatments that target underlying disease mechanisms and personalized medicine approaches that account for genetic variations among patients. The emergence of digital health technologies, including biomarkers for early diagnosis and remote patient monitoring, presents further avenues for innovation. Recommendations for businesses include investing in partnerships with academic institutions and biotech companies to leverage cutting-edge research and accelerate drug discovery. Companies should also focus on expanding market presence in regions like Asia-Pacific, where aging demographics present considerable growth potential. Market limitations such as the complexity of neurodegenerative diseases, uncertain long-term treatment efficacy, and potential side effects pose ongoing challenges. Nevertheless, areas such as neuroprotective agents, regenerative medicine, and data-driven approaches leveraging AI for drug discovery offer promising prospects for market players. The nature of the dementia drugs market remains highly competitive and research-driven, necessitating continuous innovation and strategic collaboration to effectively address unmet needs and capitalize on emerging opportunities.

Understanding Market Dynamics in the Dementia Drugs Market

The Dementia Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing geriatric population base
    • Increase in prevalence of Alzheimer disease
    • Government funding & awareness programs for Alzheimer disease
  • Market Restraints
    • High costs of research and drug development
  • Market Opportunities
    • Continuous growth in popularity of online pharmacy services due to providing safe and reliable access to medication
    • Advancement of new drugs and treatments
    • Advancing therapeutic and biomarker development for Alzheimer's and related dementias created funding opportunities
  • Market Challenges
    • Complex pathology and etiology and no biomarkers for early detection of the disease

Exploring Porter’s Five Forces for the Dementia Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Dementia Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Dementia Drugs Market

External macro-environmental factors deeply influence the performance of the Dementia Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Dementia Drugs Market

The Dementia Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Dementia Drugs Market

The Dementia Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Dementia Drugs Market

The Dementia Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dementia Drugs Market, highlighting leading vendors and their innovative profiles. These include Anavex Life Sciences Corp., AstraZeneca PLC, Aurobindo Pharma Limited, Biogen Inc., Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Quidel Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Dementia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Indications
    • Alzheimer's Disease
    • Lewy Body Dementia
    • Parkinsons Disease Dementia
    • Vascular Dementia
  • Drug Class
    • Cholinesterase Inhibitors
    • Glutamate Inhibitors
    • MAO Inhibitors
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing geriatric population base
5.1.1.2. Increase in prevalence of Alzheimer disease
5.1.1.3. Government funding & awareness programs for Alzheimer disease
5.1.2. Restraints
5.1.2.1. High costs of research and drug development
5.1.3. Opportunities
5.1.3.1. Continuous growth in popularity of online pharmacy services due to providing safe and reliable access to medication
5.1.3.2. Advancement of new drugs and treatments
5.1.3.3. Advancing therapeutic and biomarker development for Alzheimer's and related dementias created funding opportunities
5.1.4. Challenges
5.1.4.1. Complex pathology and etiology and no biomarkers for early detection of the disease
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Dementia Drugs Market, by Indications
6.1. Introduction
6.2. Alzheimer's Disease
6.3. Lewy Body Dementia
6.4. Parkinsons Disease Dementia
6.5. Vascular Dementia
7. Dementia Drugs Market, by Drug Class
7.1. Introduction
7.2. Cholinesterase Inhibitors
7.3. Glutamate Inhibitors
7.4. MAO Inhibitors
8. Americas Dementia Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Dementia Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Dementia Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. DEMENTIA DRUGS MARKET RESEARCH PROCESS
FIGURE 2. DEMENTIA DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. DEMENTIA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DEMENTIA DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LEWY BODY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PARKINSONS DISEASE DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MAO INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. CANADA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 24. CANADA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. MEXICO DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 26. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 31. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 34. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. CHINA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 36. CHINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. INDIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 38. INDIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 40. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. JAPAN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 42. JAPAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 44. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 46. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 48. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 50. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. TAIWAN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 52. TAIWAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. THAILAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 54. THAILAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. VIETNAM DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 56. VIETNAM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. DENMARK DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 61. DENMARK DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. EGYPT DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 63. EGYPT DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. FINLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 65. FINLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. FRANCE DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 67. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. GERMANY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 69. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 71. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. ITALY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 73. ITALY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 75. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 77. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. NORWAY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 79. NORWAY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. POLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 81. POLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. QATAR DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 83. QATAR DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 85. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 87. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 89. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. SPAIN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 91. SPAIN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 93. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 95. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. TURKEY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 97. TURKEY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 103. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Dementia Drugs Market, which are profiled in this report, include:
  • Anavex Life Sciences Corp.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Forest Laboratories, Inc.
  • Janssen Global Services, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Quidel Corporation
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Zydus Cadila

Methodology

Loading
LOADING...

Table Information